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Background: Women whose pregnancies are affected by hypertensive disorders of pregnancy, in particular
preterm pre-eclampsia, are at increased risk of long-term cardiovascular morbidity and mortality.
Objectives: To investigate the hypothesis that prolongation of a pregnancy affected by preterm
pre-eclampsia managed by expectant management compared with planned early delivery would result
in worse cardiovascular function 6 months postpartum.
Design: A randomised controlled trial.
Setting: 28 maternity hospitals in England and Wales.
Participants: Women who were eligible for the Pre-eclampsia in HOspital: Early iNductIon or
eXpectant management (PHOENIX) study were approached and recruited for the PHOEBE study.
The PHOENIX (Pre-eclampsia in HOspital: Early iNductIon or eXpectant management) study was
a parallel-group, non-masked, multicentre, randomised controlled trial that was carried out in
46 maternity units across England and Wales. This study compared planned early delivery with
expectant management (usual care) with individual randomisation in women with late preterm
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pre-eclampsia who were 34 weeks’ gestation to less than 37 weeks’ gestation and having a singleton
or dichorionic diamniotic twin pregnancy.
Interventions: Postpartum follow-up included medical history, blood pressure assessment and
echocardiography. All women had blood sampling performed on at least two time points from
recruitment to the 6-month follow-up for assessment of cardiac necrosis markers.
Main outcome measures: Primary outcome was a composite of systolic and/or diastolic dysfunction
(originally by 2009 guidelines then updated by 2016 guidelines, with an amended definition of diastolic
dysfunction). Analyses were by intention to treat, together with a per-protocol analysis for the primary
and secondary outcomes.
Results: Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom
420 (67%) were recruited across 28 maternity units in England and Wales. A total of 133 women were
allocated to planned delivery, 137 women were allocated to expectant management and a further 150
received non-randomised expectant management within usual care. The mean time from enrolment to
delivery was 2.5 (standard deviation 1.9) days in the planned delivery group compared with 6.8 (standard
deviation 5.3) days in the expectant management group. There were no differences in the primary outcome
between women in the planned delivery group and those in the expectant management group using either
the 2009 (risk ratio 1.06, 95% confidence interval 0.80 to 1.40) or the 2016 definition (risk ratio 0.78,
95% confidence interval 0.33 to 1.86). Overall, 10% (31/321) of women had a left ventricular ejection
fraction < 55% and 71% of the cohort remained hypertensive at 6 months postpartum. No differences
were observed between groups in cardiorespiratory outcomes prior to discharge from hospital or in
systolic or diastolic blood pressure measurements. Variables associated with the primary outcome
(2009 definition) at 6 months postpartum were maternal body mass index (adjusted odds ratio 1.33 per
5 kg/m2, 95% confidence interval 1.12 to 1.59 per 5 kg/m2) and maternal age (adjusted odds ratio 2.16,
95% confidence interval 1.44 to 3.22 per 10 years). Limitations include changing definitions regarding
systolic and/or diastolic dysfunction.
Conclusions: Preterm pre-eclampsia results in persistence of hypertension in the majority of women
with late preterm pre-eclampsia at 6 months postpartum and systolic dysfunction in 10%. Pre-eclampsia
should not be considered a self-limiting disease of pregnancy alone.
Future work: Interventions aimed at reducing cardiovascular dysfunction.
Trial registration: Current Controlled Trials ISRCTN01879376.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme,
a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be
published in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 12. See the NIHR Journals Library
website for further project information.
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FIGURE 1 Participant flow chart 7
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TDI tissue Doppler imaging
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Women who have a form of high blood pressure in pregnancy called pre-eclampsia may be atrisk of heart disease later in life. When a woman becomes unwell with this type of high blood
pressure in pregnancy we usually wait until she is 37 weeks pregnant before recommending delivery.
We carried out a study to see if earlier delivery would lead to fewer complications for the woman and
the baby, and to see if this would also reduce her risk of damage to her heart after pregnancy.
This study was part of a larger study called the Pre-eclampsia in HOspital: Early iNductIon or eXpectant
management (PHOENIX) study. In this study, women with pre-eclampsia between 34 and 37 weeks of
pregnancy either had birth started within 48 hours (usually by induction of labour) or underwent usual
care, waiting until the doctor thought that she needed delivery or she reached 37 weeks of pregnancy.
In our study, we invited women back 6 months after having their baby, performed an ultrasound of their
hearts and checked blood pressure. We then looked to see whether or not being delivered earlier
caused less damage to the heart.
Between April 2016 and November 2018, 420 women in 28 hospitals in the England and Wales agreed
to take part.
We showed that staying pregnant with pre-eclampsia for a few days longer did not cause more heart
damage. However, 1 in 10 women in the study had ultrasound evidence of damage to their hearts.
Over half of the women in the study did not have a normal ultrasound of their heart. Around 7 out of
10 of these women with pre-eclampsia still had high blood pressure 6 months after their pregnancy.
These findings suggest that these women need more intensive monitoring and follow-up after their
pregnancy. This might help reduce the long-term risks of heart disease.
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Pre-eclampsia affects 3–5% of pregnancies, complicating approximately 35,000 pregnancies in the UK
every year. Cardiovascular disease is the leading cause of mortality in women in the UK. Hypertensive
disorders of pregnancy, in particular preterm pre-eclampsia, have been shown to be associated with an
increased risk of development of a wide range of cardiovascular diseases, with increases in incidences
observed as soon as 1 year postpartum. The absolute risk that a woman with pre-eclampsia would
develop a cardiovascular event including hypertension, ischaemic heart disease, stroke or venous
thromboembolism when she reaches the age of 50–59 years is estimated to be 17.8%, compared with
8.3% in those without pre-eclampsia.
The Pre-eclampsia in HOspital: Early iNductIon or eXpectant management (PHOENIX) study, a
multicentre, randomised controlled trial, recruited women with late preterm pre-eclampsia who were
34 weeks’ gestation to less than 37 weeks’ gestation and having a singleton or dichorionic diamniotic
twin pregnancy. It demonstrated that initiation of planned delivery in the subsequent 48 hours after
randomisation reduced severe maternal adverse outcomes with no difference in neonatal morbidity
(but there were more neonatal unit admissions) compared with the current practice of expectant
management until 37 weeks’ gestation. This PHOENIX study provided a key opportunity to examine
the mechanisms underlying cardiovascular dysfunction following a randomised intervention on timing
of delivery. An associated editorial alongside the main trial publication questioned whether initiating
delivery in late preterm pre-eclampsia rather than waiting until term might theoretically reduce the
stress on the woman’s cardiovasculature (Staff AC. Long-term cardiovascular health after stopping
pre-eclampsia. Lancet 2019;394:1120–1). The editorial advised evaluating whether or not a change to
active delivery of women with late preterm pre-eclampsia would also benefit maternal cardiovascular
health in the long term.
We conducted a follow-up cardiovascular assessment of women eligible for the PHOENIX study to
examine the hypothesis that planned delivery in women with preterm pre-eclampsia, with attendant
myocardial ischaemia, may decrease the risk of the development of cardiovascular dysfunction
following pregnancy.
Objectives
The main aim of this mechanistic study was to examine the effects of shortening pregnancy
complicated by pre-eclampsia on cardiovascular function at 6 months postpartum by studying women
enrolled in a randomised controlled trial of planned delivery compared with usual care (expectant
management) and who had late preterm pre-eclampsia.
Methods
Study design and participants
In this parallel-group, non-masked, multicentre, randomised controlled trial, we compared cardiovascular
function at 6 months postpartum in women with preterm pre-eclampsia who were managed by planned
delivery against expectant management (usual care). This trial was carried out in 28 consultant-led
maternity units in England and Wales. Participants who were eligible for the PHOENIX study were
approached following their decision to participate. A pregnant woman was eligible if she was between
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34+0 and 36+6 weeks’ gestation, had a diagnosis of pre-eclampsia or superimposed pre-eclampsia
[as defined by the International Society for the Study of Hypertension in Pregnancy (Tranquilli AL,
Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management
of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens
2014;4:97–104)], with a singleton or dichorionic diamniotic twin pregnancy and at least one viable
fetus, was aged ≥ 18 years, and was able to give written informed consent. The only exclusion criterion
to study participation was if a decision had already been made to deliver her baby in the next 48 hours.
There were no substantial changes to the published study design, methods or outcomes after the start
of the trial. The trial was approved by the South Central – Hampshire B Research Ethics Committee
(number 13/SC/0645).
Randomisation and masking
Participants were randomly assigned to planned delivery or expectant care in a 1 : 1 ratio, as previously
described. When women declined participation in the PHOENIX study, participation in the PHOEBE
study was offered and these women were included as a third, non-randomised expectant (usual-care)
group. The intervention was not masked from women, clinicians or data collectors because of the
nature of the intervention. Trial statisticians were also not masked to allocation. However, the trial
echocardiographer (JOD) was blinded to allocation group in analysis of all echocardiograms.
Procedures
Women were approached about participating in the PHOENIX study. Regardless of their participation
in the PHOENIX study, site research teams approached women to confirm their eligibility and to
provide verbal and written information. A trained research midwife or clinician obtained written
informed consent. A research team member entered baseline data on a web-based database. All other
aspects of pregnancy management were expected to be in accordance with the UK national guidelines
at the discretion of the responsible clinician. Outcomes were recorded on the web-based trial database
through case note review by trained researchers after maternal primary hospital discharge. Women
were invited to return to their local hospital at least 6 months following delivery for echocardiography
assessment, which was performed within an 8-week window. At this assessment, a brief medical history
was recorded, blood pressure was assessed, and venepuncture and echocardiography were undertaken.
Echocardiography was performed locally in accordance with a standard operating procedure circulated
by the research team. Anonymised echocardiography discs were then sent to the lead echocardiographer
(JOD), who analysed each echocardiogram without knowledge of trial allocation and entered results
into the web-based trial database. Every tenth echocardiogram was second read, again masked to trial
allocation, by an echocardiographer at the University of Oxford and the findings were compared by the
trial lead cardiologist (PL) to ensure consistency. When echocardiography assessment demonstrated
potentially concerning features that may have an impact on clinical care, the findings were escalated
and reviewed by the lead cardiologist (PL) and communicated back to the lead clinician at the recruiting
site with a clinical recommendation for follow-up.
Outcomes
The primary outcome was a composite of diastolic and systolic function at 6 months postpartum classified
according to the joint recommendation by the American Society of Echocardiography and the European
Association of Cardiovascular Imaging as assessed by transthoracic echocardiography with tissue Doppler
studies, originally classified in 2009 and updated prior to study completion in 2016. Secondary outcomes
included systolic blood pressure and diastolic blood pressure at 6 months postpartum, together with
the cardiovascular components of the fullPIERS (Preeclampsia Integrated Estimate of RiSk) composite
maternal morbidity outcome, which was adapted from the fullPIERS prediction of adverse events in
pre-eclampsia study. The cardiovascular components from the maternal morbidity composite outcome in
the PHOENIX study included severe hypertension post randomisation (systolic blood pressure ≥ 160mmHg
on at least one occasion), positive inotropic support, infusion of a third parenteral antihypertensive drug,
myocardial ischaemia or infarction, oxygen saturation (SpO2) < 90%, ≥ 50% fraction of inspired oxygen for
> 1 hour, intubation (other than for caesarean section) and pulmonary oedema.
SCIENTIFIC SUMMARY
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Echocardiographic assessment
All participants were studied by standard two-dimensional and Doppler transthoracic echocardiography at
rest.Women were studied in the left lateral decubitus position and data were acquired at end-expiration
from standard parasternal/apical views using a GE Vivid (GE Medical Systems Ltd, Chalfont St Giles, UK)
or Philips (Philips Electronics UK, Farnborough, UK) scanner. For each acquisition, three cardiac cycles
of non-compressed data were stored in cine-loop format and analysed by one investigator (JOD), who
was masked to the group allocation, with a second read as described above. Cardiac indices were
normalised for body surface area, height and end-diastolic left ventricle long- or short-axis lengths, as
appropriate. Tissue Doppler imaging, strain and strain rate indices are given as absolute values. Details
of measurements of heart remodelling, systolic and diastolic dysfunction are also described.
Myocardial necrosis assessment
Participants were also consented to at least two blood sampling time points, most commonly
performed at initial recruitment and the 6-month postpartum assessment. These samples were
analysed for markers of myocardial necrosis/ischaemia: highly sensitive cardiac troponin-Is. High-
sensitivity troponin-Is concentration in patients with stable cardiovascular disease identify those at
increased risk of future myocardial infarction and other ischaemic cardiac outcomes (McQueen MJ,
Kavsak PA, Xu L, Shestakovska O, Yusuf S. Predicting myocardial infarction and other serious cardiac
outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clin Biochem
2013;46:5–9). A sex-specific level of > 16 ng/l of high-sensitivity troponins was considered to be an
elevated level in women. Cardiac myosin-binding protein C was also measured at 6 months postpartum
using Singulex’s (Alameda, CA, USA) Single Molecule Counting Technology SMC™, a quantitative
fluorescent sandwich immunoassay technique. The level of a third biomarker, N-terminal pro-brain
natriuretic peptide (a marker used in the assessment of patients with heart failure), was also assessed
at 6 months postpartum.
Statistical analysis
Assuming an anticipated incidence of 70% of women with preterm pre-eclampsia having evidence
of systolic and/or diastolic dysfunction at 6 months postpartum, a sample size of 322 women was
needed to detect a 25% relative risk reduction (from 70% to 52.5%; deemed clinically important)
in the primary outcome in the planned delivery group compared with those managed expectantly
with a two-sided 5% significance level and 90% power. With a 20% loss of women at follow-up, the
overall target for recruitment was 404 women (202 per group). The primary analysis for all maternal
outcomes was by intention to treat, with participants analysed in the groups to which they were
assigned regardless of protocol non-compliances. Risk ratios were estimated for binary outcomes
with associated 95% confidence intervals. Simple and multiple regression analysis were used to assess
the influence of early pregnancy factors, including blood pressure, demographic variables (maternal
age, body mass index), pregnancy characteristics (parity, gestation at delivery, gestation at onset
and severity of pre-eclampsia), on indices of cardiac function and remodelling, as detailed above
(see Outcomes). All of the conventional echocardiographic indices were adjusted for body surface
area and all of the tissue Doppler velocity and deformation indices to the end-diastolic left or right
ventricle long-axis length. Prespecified subgroup analyses were carried out for co-primary outcomes
in view of the changes to definitions of systolic and diastolic dysfunction over the study period.
Data analyses were carried out with Stata/SE® (StataCorp LP, College Station, TX, USA) version 15.1.
Results
Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom
420 (67%) were recruited, across 28 maternity units in England and Wales. A total of 133 women
were allocated to planned delivery, 137 women were allocated to expectant management and a further
150 received non-randomised expectant management.
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For the intention-to-treat analysis, data from 100 women in the planned delivery group and from
107 women in the expectant management group were included. Follow-up to the 6-month postpartum
assessments continued until 20 June 2019. Thirty-three (25%) women were lost to follow-up in the
planned delivery group and 30 (22%) in the expectant management group. Baseline characteristics
appeared similar between the two groups, with groups well balanced on minimisation factors.
There were no differences in the primary outcome between women in the planned delivery group
(50%) compared with those in the expectant management group (47.2%) using either the 2009
(risk ratio 1.06, 95% confidence interval 0.80 to 1.40) or the 2016 definition (8.0% vs. 10.3%; risk
ratio 0.78, 95% confidence interval 0.33 to 1.86). No between-group differences were observed in
2009 diastolic dysfunction grade 1 (risk ratio 1.40, 95% confidence interval 0.59 to 3.31), grade 2
(risk ratio 1.11, 95% confidence interval 0.78 to 1.57) or grade 3 (risk ratio 1.18, 95% confidence
interval 0.08 to 18.43) diastolic dysfunction subclassifications nor in 2016 diastolic dysfunction
classification. Overall, 10% (31/321) of women had a left ventricular ejection fraction < 55% 6 months
postpartum. Similarly, using the more recent 2016 classification for systolic and diastolic dysfunction,
no differences were observed in systolic (risk ratio 0.76, 95% confidence interval 0.32 to 1.80) or any
of the diastolic dysfunction parameters. Hypertension prevalence, defined as on antihypertensive
treatment or systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at 6 months
postpartum, was similar between those managed with planned delivery and those expectantly managed
(risk ratio 1.01, 95% confidence interval 0.85 to 1.20) but, overall, was present in 71% of the cohort.
No significant differences were observed in any of the cardiac parameters including geometric and
haemodynamic parameters, left ventricular global cardiac parameters, myocardial mechanics and left
ventricular basal or apical parameters between those women with planned delivery and those who
were expectantly managed.
The only variables that were predictive of systolic and/or diastolic dysfunction at 6 months postpartum
were maternal body mass index (adjusted odds ratio 1.33 per 5 kg/m2, 95% confidence interval 1.12 to
1.59 per 5 kg/m2) and maternal age (adjusted odds ratio 2.16, 95% confidence interval 1.44 to 3.22 per
10 years). The interval from study enrolment to delivery was not associated with development of the
primary outcome. All women in the planned delivery group received the trial intervention, although
this was not always initiated within 48 hours as intended. Of women allocated to the planned delivery
group, 105 (78%) out of 133 had delivery initiated within 48 hours.
Overall, 8% (n = 25) of women had their clinical echocardiograms escalated by the trial cardiologist
with clinical follow-up recommended. These were for a combination of structural (n = 8), valvular
(n = 8), functional (n = 9) or combined (n = 2) findings. These clinical escalations accounted for 12% of
those with the primary outcome, with 88% of those with systolic and/or diastolic dysfunction not
requiring clinical escalation.
Conclusions
In this randomised controlled trial of women with late preterm pre-eclampsia, planned delivery did
not reduce cardiovascular dysfunction at 6 months postpartum. The adverse cardiovascular sequelae
of preterm pre-eclampsia are substantial; 10% of women with preterm pre-eclampsia had a left
ventricular ejection fraction < 55%, 71% remained hypertensive and 49% of women had evidence of
impaired diastolic dysfunction of undetermined long-term clinical importance at 6 months postpartum.
Women in the planned delivery group had a median shortening of pregnancy from enrolment to delivery
of 4 days, but this did not result in decreased hypertension or cardiovascular dysfunction compared
with those managed with usual care by expectant management. Only elevated body mass index and a
higher age at enrolment predicted the occurrence of postpartum systolic and/or diastolic dysfunction.
SCIENTIFIC SUMMARY
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Our finding of 71% of women with preterm pre-eclampsia remaining hypertensive 6 months postpartum
is higher than reported in larger population-based cohorts, highlighting high levels of presumed
undiagnosed hypertension. It is imperative that we understand the mechanisms that contribute to
worsening risk factor profiles in young women to reduce future cardiovascular morbidity and mortality.
Our study confirms that pre-eclampsia is associated with substantial postpartum cardiovascular
dysfunction, not influenced by expectant management or planned delivery. Pre-eclampsia should not be
considered a self-limiting disease of pregnancy alone. This research improves our understanding of the
mechanistic processes linking pre-eclampsia with maternal cardiovascular impairment. The evidence
suggests that expectant management of preterm pre-eclampsia does not worsen postpartum cardiovascular
dysfunction and women can be reassured that prolongation of a pregnancy affected by preterm
pre-eclampsia will not further worsen their cardiovascular health. The study informs counselling of women
with pre-eclampsia around future risks and also identifies the postpartum period as a critical area to
target in future intervention studies. This study provides a body of evidence for postpartum cardiac
functional impairment and demonstrates the need for further research into early intervention, particularly
relating to novel therapeutic pathways.
Recommendations for research
1. What postnatal interventions are effective in reducing cardiovascular dysfunction following preterm
pre-eclampsia?
2. How can biomarker discovery improve prediction of cardiovascular dysfunction following adverse
pregnancy outcomes?
Trial registration
This trial is registered as ISRCTN01879376.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership. This will be published
in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 12. See the NIHR Journals Library website for
further project information.
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Pre-eclampsia affects 3–5% of pregnancies, complicating approximately 35,000 pregnancies inthe UK every year. Cardiovascular disease is the leading cause of mortality in women in the UK.1
Hypertensive disorders of pregnancy, in particular preterm pre-eclampsia, have been shown to be
associated with an increased risk of development of a wide range of cardiovascular diseases, with
increases in incidences observed as soon as 1 year postpartum.2 The absolute risk that a woman with
pre-eclampsia would develop a cardiovascular event including hypertension, ischaemic heart disease,
stroke or venous thromboembolism when she reaches the age of 50–59 years is estimated to be
17.8%, compared with 8.3% in those without pre-eclampsia.3 The American Heart Association now
recognises pre-eclampsia as an independent risk factor for future cardiovascular disease.4 The
economic burden of cardiovascular disease is substantial; the British Heart Foundation estimated
that in 2006 cardiovascular disease cost the NHS £14.3B and the UK economy £30.6B,5 and the cost
for EU health-care systems related to cardiovascular disease is estimated at €110B, approximately 10%
of the total health-care expenditure across the EU. With an increasingly ageing population, costs are
set to rise further.
To date, only case–control studies and small single-centre cohort studies exist to provide evidence of
association between pre-eclampsia and persistent cardiovascular dysfunction. Although some women
have pre-existing risk factors for pre-eclampsia that also predispose to cardiovascular disease and
for whom pre-eclampsia may accelerate progression through adding a further stress, in others,
pre-eclampsia occurs with no pre-existing factors and may be the first ‘hit’ in the pathway. The most
likely explanation for the additional impact from pre-eclampsia is subclinical myocardial injury caused
by the underlying pathophysiology. This proposed research seeks to elucidate the role and extent of
myocardial stress in determining subsequent cardiac dysfunction.
The Pre-eclampsia in HOspital: Early iNductIon or eXpectant management (PHOENIX) study, a multicentre
randomised controlled trial, recruited women with late preterm pre-eclampsia who were 34 weeks’
gestation to less than 37 weeks’ gestation and having a singleton or dichorionic diamniotic twin pregnancy.6
It demonstrated that initiation of planned delivery within the subsequent 48 hours after randomisation
reduced severe maternal adverse outcomes with no difference in neonatal morbidity (but there were
more neonatal unit admissions) compared with the current practice of expectant management until
37 weeks’ gestation. This PHOENIX study provided a key opportunity to examine the mechanisms
underlying cardiovascular dysfunction following a randomised intervention on timing of delivery. An
associated editorial alongside the main trial publication questioned whether initiating delivery in late
preterm pre-eclampsia rather than waiting until term might theoretically reduce the stress on the woman’s
cardiovasculature.7 The editorial advised evaluating whether or not a change to active delivery of women
with late preterm pre-eclampsia would also benefit maternal cardiovascular health in the long term.
We conducted a follow-up cardiovascular assessment of women eligible for the PHOENIX study to
examine the hypothesis that planned delivery in women with preterm pre-eclampsia, with attendant
myocardial ischaemia, may decrease the risk of the development of cardiovascular dysfunction
following pregnancy. The main aim of this mechanistic study was to examine the effects of shortening
pregnancy complicated by pre-eclampsia on cardiovascular function at 6 months postpartum by
studying women enrolled in a randomised controlled trial of planned delivery compared with those
undergoing usual care (expectant management) who had late preterm pre-eclampsia.
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Study design and participants
In this parallel-group, non-masked, multicentre, randomised controlled trial, we compared
cardiovascular function at 6 months postpartum in women with preterm pre-eclampsia who
were managed by planned delivery with women managed by expectant management (usual care).
This trial was carried out in 28 consultant-led maternity units in England and Wales. Participants
who were eligible for the PHOENIX study were approached following their decision to participate.
A pregnant woman was eligible if she was between 34+0 and 36+6 weeks’ gestation, had a diagnosis
of pre-eclampsia or superimposed pre-eclampsia (as defined by the International Society for the Study
of Hypertension in Pregnancy),8 with a singleton or dichorionic diamniotic twin pregnancy and at
least one viable fetus, was aged ≥ 18 years, and was able to give written informed consent. The only
exclusion criterion to study participation was if a decision had already been made to deliver her baby
in the next 48 hours. There were no substantial changes to the published study design, methods or
outcomes after the start of the trial. The trial was approved by the South Central – Hampshire B
Research Ethics Committee (number 13/SC/0645).
Randomisation and masking
Participants were randomly assigned to planned delivery or expectant care in a 1 : 1 ratio, as previously
described.6 When women declined participation in the PHOENIX study, participation in the PHOEBE
study was offered and these women were included as a third, non-randomised expectant (usual-care)
group. The intervention was not masked from women, clinicians or data collectors because of the
nature of the intervention. Trial statisticians were also not masked to allocation. However, the trial
echocardiographer (JOD) was blinded to allocation group in analysis of all echocardiograms.
Procedures
Women were approached for participation into the PHOENIX study. Regardless of their participation in
the PHOENIX study, site research teams approached women to confirm their eligibility and to provide
verbal and written information. A trained research midwife or clinician obtained written informed
consent. A research team member entered baseline data on a web-based database. All other aspects
of pregnancy management were expected to be in accordance with the UK national guidelines at the
discretion of the responsible clinician.9 Outcomes were recorded on the web-based trial database
through case note review by trained researchers after maternal primary hospital discharge. Women
were invited to return to their local hospital at least 6 months following delivery for echocardiography
assessment, which was performed within an 8-week window. At this assessment, a brief medical history
was recorded, blood pressure was assessed, and venepuncture and echocardiography were undertaken.
Echocardiography was performed locally in accordance with a standard operating procedure circulated
by the research team. Anonymised echocardiography discs were then sent to the lead echocardiographer
(JOD), who analysed each echocardiogram without knowledge of trial allocation and entered results
into the web-based trial database. Every tenth echocardiogram was second read, again masked to trial
allocation, by an echocardiographer at the University of Oxford and the findings were compared by the
trial lead cardiologist (PL) to ensure consistency. When echocardiography assessment demonstrated
potentially concerning features that may have an impact on clinical care, the findings were escalated
and reviewed by the lead cardiologist (PL) and communicated back to the lead clinician at the recruiting
site with a clinical recommendation for follow-up.
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Outcomes
The primary outcome was a composite of diastolic and systolic function at 6 months postpartum
classified according to the joint recommendation by the American Society of Echocardiography and the
European Association of Cardiovascular Imaging as assessed by transthoracic echocardiography with
tissue Doppler studies classified originally in 200910 and reclassified prior to study completion in 2016.11
Tissue Doppler velocity and deformation indices have been shown to be highly sensitive at detecting
even mild myocardial damage.12–15 The primary outcome was chosen to integrate the subclinical
myocardial injury that occurs in the long term as well as that resulting from the different time exposed
to pre-eclampsia resulting from the randomised intervention in the PHOENIX study. The cardiovascular
components from the maternal morbidity composite outcome in the PHOENIX study included severe
hypertension post randomisation (systolic blood pressure ≥ 160 mmHg on at least one occasion), positive
inotropic support, infusion of a third parenteral antihypertensive drug, myocardial ischaemia or infarction,
oxygen saturation (SpO2) < 90%, ≥ 50% fraction of inspired oxygen (FiO2) for > 1 hour, intubation (other
than for caesarean section) and pulmonary oedema. The composite was chosen as an internationally
accepted validated method for predicting adverse maternal outcome from pre-eclampsia.16
Echocardiographic assessment
All participants were studied by standard two-dimensional and Doppler transthoracic echocardiography
at rest. Women were studied in the left lateral decubitus position and data were acquired at end-
expiration from standard parasternal/apical views using a GE Vivid (GE Medical Systems Ltd, Chalfont
St Giles, UK) or Philips (Philips Electronics UK, Farnborough, UK) scanner.10,17 For each acquisition,
three cardiac cycles of non-compressed data were stored in cine-loop format and analysed by one
investigator (JOD), who was masked to the group allocation, with a second read as described above.
Cardiac indices were normalised for body surface area, height and end-diastolic left ventricle long or
short axis lengths, as appropriate.18–20 Tissue Doppler imaging (TDI), strain and strain rate indices are
given as absolute values.
Heart remodelling
Chamber quantification and left ventricular geometric pattern were estimated using M-mode, as
previously described.17 Proximal septal bulging was assessed in the parasternal long-axis and apical
four-chamber views.21
Systolic and diastolic dysfunction
Global left ventricular diastolic function, estimated filling pressures on the left side of the heart and
geometry were assessed and graded using standard diagnostic algorithms with the recommended
adjustments reflecting the concomitant systolic function and age.22 Left ventricular volumes and
ejection fractions were derived from Simpson’s modified biplane method from apical four-chamber and
two-chamber views, and left ventricular systolic dysfunction was defined as ejection fraction < 55%.17
Haemodynamic and systolic cardiac indices were calculated as previously described.23 Longitudinal
and radial systolic function were assessed both globally and regionally using colour and pulsed tissue
Doppler velocity indices and strain rate indices using speckle tracking, as previously described.24–28
Regional peak systolic strain rate index was considered abnormal if it was two standard deviations
below the expected mean for age.29 This abnormality was defined as segmental myocardial impaired
contractility. Regional diastolic dysfunction was defined as early to late strain rate ratio < 1. This
abnormality was defined as segmental impaired myocardial relaxation. Maternal blood pressure was
measured following the recommendations of the International Society for the Study of Hypertension
in Pregnancy and National High Blood Pressure Education Programme Working Group on High Blood
Pressure in Pregnancy.30,31
METHODS
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The left ventricular global systodiastolic dysfunction was defined as left ventricular global diastolic
dysfunction in the presence of reduced ejection fraction (< 55%). Function and remodelling of the right
heart were assessed using conventional echocardiography, tissue Doppler and myocardial deformation
indices following published guidelines. The severity of left and right ventricular hypertrophy and
dysfunction was graded according to the European Association and American Society of Echocardiography
guidelines,10,17 with the following adjustments described by Melchiorre et al.:24 age, increased circulating
volume in pregnancy, and the acute nature of pre-eclampsia on a previously normal cardiovascular system.
For our primary outcome, diastolic dysfunction was classified as normal, impaired myocardial relaxation
with normal left ventricular end-diastolic pressure (grade 1), pseudonormal filling pattern (grade 2) and
restrictive pattern (grade 3).24 Findings were also reported in accordance with ASE/EACVI 2016 guidelines,11
published after study conception and the start of recruitment.
Secondary outcomes included systolic blood pressure and diastolic blood pressure at 6 months
postpartum, together with the cardiovascular components of the fullPIERS composite maternal
morbidity outcome adapted from the fullPIERS prediction of adverse events in pre-eclampsia study.16,32
Myocardial necrosis assessment
Participants were also consented to at least two blood sampling time points, most commonly
performed at initial recruitment and the 6-month postpartum assessment. These samples were
analysed for markers of myocardial necrosis/ischaemia: highly sensitive cardiac troponin-Is (cTnIs).
High-sensitivity troponin concentrations in patients with stable cardiovascular disease identify those at
increased risk for future myocardial infarction and other ischaemic cardiac outcomes.33 A sex-specific
level of > 16 ng/l of high-sensitivity troponins was considered to be an elevated level in women.34
Cardiac myosin-binding protein C (cMyC) was also measured at 6 months postpartum using Singulex’s
Single Molecule Counting Technology SMC™, a quantitative fluorescent sandwich immunoassay
technique. A third biomarker, N-terminal pro-brain natriuretic peptide, a marker used in the
assessment of patients with heart failure, was also assessed at 6 months postpartum.
Statistical analysis
Assuming an anticipated incidence of 70% of women with preterm pre-eclampsia having evidence of
systolic and/or diastolic dysfunction at 6 months postpartum,24,35,36 a sample size of 322 women was
needed to detect a 25% relative risk reduction (from 70% to 52.5%; deemed clinically important) in
the primary outcome in the planned delivery group compared with those managed expectantly with a
two-sided 5% significance level and 90% power. With a 20% loss of women at follow-up, the overall
target for recruitment was 404 women (202 per group). The primary analysis for all maternal outcomes
was by intention to treat with participants analysed in the groups to which they were assigned regardless
of protocol non-compliances. Power calculations were carried out in Stata® (StataCorp LP, College Station,
TX, USA) version 13.1.
Risk ratios were estimated for binary outcomes with associated 95% confidence intervals (CIs).
Simple and multiple regression analysis were used to assess the influence of early pregnancy factors,
including blood pressure, demographic variables [maternal age, body mass index (BMI)], pregnancy
characteristics (parity, gestation at delivery, gestation at onset and severity of pre-eclampsia), on
indices of cardiac function and remodelling, as detailed above (see Outcomes). All of the conventional
echocardiographic indices were adjusted for body surface area17 and all of the tissue Doppler velocity
and deformation indices to the end-diastolic left or right ventricle long-axis length.18 Prespecified subgroup
analyses were carried out for co-primary outcomes in view of the changes to definitions of systolic and
diastolic dysfunction over the study period. Data analyses were carried out with Stata/SE version 15.1.
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Between 27 April 2016 and 30 November 2018, 623 women were found to be eligible, of whom420 (67%) were recruited, across 28 maternity units in England and Wales. A total of 133 women
were allocated to planned delivery, 137 women were allocated to expectant management and a further
150 received non-randomised expectant management (Figure 1).
For the intention-to-treat analysis, data from 100 women in the planned delivery group and 107 women
in the expectant management group were included. Follow-up to the 6-month postpartum assessments
continued until 20 June 2019. Thirty-three (25%) women were lost to follow-up in the planned delivery
group and 30 (22%) in the expectant management group (see Figure 1). Baseline characteristics appeared
similar between the two groups, with groups well balanced on minimisation factors (Table 1).
The enrolment characteristics are shown in Table 2.




Consented to the PHOEBE study
(n = 420)
Received non-randomised expectant
management (within usual care)
(n = 150)
• Received expectant management,
    n = 150
• Did not receive expectant
    management, n = 0
Analysis population followed up
at 6 months
(n = 114)
• Excluded from analysis, n = 0
• Did not attend 6-month follow-up,
    n = 36
Consented to the PHOENIX study
(randomised timing of delivery)
and the PHOEBE study
(n = 270)
Analysis population followed up
at 6 months
(n = 100)
• Excluded from analysis, n = 0
• Did not attend 6-month




• Received expectant management,
    n = 137
• Did not receive expectant
    management, n = 0
Analysis population followed up
at 6 months
(n = 107)
• Excluded from analysis, n = 0
• Did not attend 6-month
    follow-up, n = 29
• Gave bloods but declined
    echocardiography, n = 1
Declined participation, n = 203
Excluded/non-eligible, n = 679
• Received planned delivery, 
    n = 133a
• Did not receive planned delivery,




FIGURE 1 Participant flow chart. a, 28 women did not receive initiation of planned delivery within 48 hours due to
clinical decision (n = 2), labour ward being too busy (n = 15), a shortage of neonatal cots (n= 5), or other reasons (n= 6).
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TABLE 1 Baseline maternal demographic and pregnancy characteristics at trial entry for all women who underwent







Age at randomisation (years),
mean (SD)
30.56 (6.11) 31.26 (6.14) 32.81 (5.18)
Ethnicity, n (%)
White 76 (76.0) 83 (77.6) 70 (61.4)
Asian 13 (13.0) 10 (9.3) 19 (16.7)
Black 8 (8.0) 6 (5.6) 20 (17.5)
Mixed 2 (2.0) 6 (5.6) 2 (1.8)
Other 1 (1.0) 2 (1.9) 3 (2.6)
Deprivation Index quintile, n (%)
1 (most deprived) 38 (38.0) 39 (36.4) 46 (40.4)
2 23 (23.0) 28 (26.2) 26 (22.8)
3 14 (14.0) 12 (12.1) 19 (16.7)
4 13 (13.0) 20 (18.7) 18 (15.8)
5 (least deprived) 12 (12.0) 7 (6.5) 5 (4.4)
Parity (previous pregnancies ≥ 24 weeks’ gestation),a n (%)
0 64 (64.0) 68 (64) 75 (66)
1 24 (24.0) 19 (18) 26 (23)
2 4 (4.0) 11 (10) 7 (6)
> 2 8 (8.0) 9 (8) 6 (5)
Previous pregnancies < 24 weeks’ gestation, n (%)
0 22 (39.3) 23 (46.0) 21 (35.6)
1 19 (33.9) 14 (28.0) 28 (47.5)
2 11 (19.6) 8 (13.0) 5 (8.5)
> 2 4 (7.1) 5 (10.0) 5 (8.5)
Previous caesarean section,a n (%) 13 (13) 19 (18) 20 (34)
History of pre-eclampsia, n (%) 15 (15) 17 (16) 19 (17)
BMI at booking (kg/m2), mean (SD) 30.2 (9.0) 30.0 (7.4) 30.3 (6.2)
Smoking status at booking, n (%)
Never smoked 81 (81) 79 (73.8) 97 (85.1)
Quit before booking 14 (14) 22 (20.6) 11 (9.6)
Smoking at booking 5 (5.0) 6 (5.6) 6 (5.3)
Blood pressure 48 hours prior to enrolment (mmHg),a n (%)
Systolic (mean, SD) 153 (15) 155 (15) 154 (15)
Diastolic (mean, SD) 96 (10) 96 (11) 94 (9)
SD, standard deviation.
a Minimisation factors used in the PHOENIX study to ensure balance at randomisation.
RESULTS
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Gestational age at enrolmenta (weeks)
Median (IQR) 35.6 (34.9–36.2) 35.6 (34.7–36.1) 34.4 (34.4–34.4)
34+0 to 34+6, n (%) 28 (28.0) 32 (29.9) 46 (40.4)
35+0 to 35+6, n (%) 34 (34.0) 38 (35.5) 35 (30.7)
36+0 to 36+6, n (%) 38 (38.0) 37 (34.6) 33 (28.9)
Pregnancy type,a n (%)
Singleton 90 (90.0) 96 (89.7) 110 (96)
Twin 10 (10.0) 11 (10.3) 4 (4)
Comorbidity at study entry (non-exclusive), n (%)
Pre-existing chronic hypertension 11 (11.0) 13 (12.1) 13 (11.4)
Pre-existing chronic renal disease 2 (2.0) 1 (0.9) 0 (0.0)
Pre-pregnancy diabetes 6 (6.0) 3 (2.8) 9 (7.9)
Gestational diabetes 14 (14.0) 12 (11.2) 14 (12.3)
Severity of hypertension in 48 hours prior to enrolmenta,b (mmHg)
Systolic BP, mean (SD) 153 (14) 155 (15) 154 (15)
Diastolic BP, mean (SD) 96 (10) 96 (10) 94 (9)
≤ 149, n (%) 41 (41.0) 38 (35.5) 45 (39.5)
150–159, n (%) 28 (28.0) 34 (31.8) 29 (25.4)
≥ 160, n (%) 31 (31.0) 35 (32.7) 40 (35.1)
Oral antihypertensive medications at study entry, n (%)
0 agents 21 (21.0) 15 (14.0) 17 (14.9)
1 agent 53 (53.0) 59 (55.1) 59 (51.8)
≥ 2 agents 26 (26.0) 33 (30.8) 38 (33.3)
Aspirin prescribed during pregnancy,
n (%)
47 (47.0) 42 (39.3) 49 (43.0)
LMWH prescribed at enrolment,
n (%)
32 (32.0) 38 (35.5) 44 (38.6)
Most recent lab parameters prior to study entry, mean (SD)
Protein–creatinine ratio (mg/mol) 137 (160) 210 (389) 128 (151)
Haemoglobin (g/l) 117 (11) 117 (12) 115 (12)
Platelets (×109/l) 228 (101) 207 (52) 217 (65)
Creatinine (µmol/l) 58 (14) 61 (12) 63 (15)
Alanine aminotransferase (U/l) 25 (28) 22 (34) 30 (43)
Aspartate aminotransferase (U/l) 125 (295) 20 (9) 22 (18.31)
Suspected fetal growth restriction,
n (%)
22 (27.8) 20 (20.4) 21 (20.6)
continued
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There were no differences between women in the planned delivery group compared with the expectant
management group in the primary outcome using either the 200910 [risk ratio (RR) 1.06, 95% confidence
interval (CI) 0.80 to 1.40] or the 2016 definition11 (RR 0.78, 95% CI 0.33 to 1.86), shown in Table 3.
No between-group differences were observed in 2009 diastolic dysfunction grade 1 (RR 1.40, 95% CI
0.59 to 3.31), grade 2 (1.11, 95% CI 0.78 to 1.57) or grade 3 (1.18, 95% CI 0.08 to 18.43) diastolic
dysfunction subclassification nor in 2016 diastolic dysfunction classification. Overall, 10% (31/321) of







Antenatal ultrasound findings, n (%)
AC < 10th 5 (6.3) 4 (4.1) 5 (6.3)
EFW < 10th 18 (22.8) 19 (19.4) 17 (16.7)
Umbilical artery PI > 95th 5 (6.3) 1 (1.0) 3 (2.9)
AREDF 0 (0.0) 0 (0.0) 2 (2.0)
AFI < 5th 2 (2.5) 1 (1.0) 2 (2.0)
Inpatient at time of trial entry
Yes 75 (75.0) 90 (84.1) 97 (85.1)
Biomarkers at enrolment
Highly sensitive cardiac troponin-I,
median (IQR) (ng/l)
5 (5–5) 5 (5–6) 5 (5–6)
> 16 ng/l, n (%) 0 (0) 2 (1.9) 4 (3.6)
AC, abdominal circumference; AFI, amniotic fluid index; AREDF, absent to reverse end-diastolic flow; BP, blood pressure;
EFW, estimated fetal weight; IQR, interquartile range; LMWH; low-molecular-weight heparin; PI, pulsatility index;
SD, standard deviation.
a Minimisation factors used to ensure balance at randomisation.
b These are summary statistics for the mean of an individual’s two BP readings.












Primary outcome (2009 definition),10 n/N (%)
Diastolic and/or systolic dysfunction
postpartum
50/100 (50.0) 50/106 (47.2) 1.06 (0.80 to 1.40) 164 (51)
Systolic dysfunction (yes/no) defined
as left ventricular ejection fraction
< 55%
8/98 (8.2) 11/102 (10.8) 0.76 (0.32 to 1.80) 31 (10)
Diastolic dysfunction subclassification,a n (%) N = 96 N = 103
Normal 48 (50.0) 57 (55.3) 157 (51)
Impaired myocardial relaxation with
normal left ventricular end-diastolic
pressure (grade 1)
10 (10.4) 8 (7.8) 1.40 (0.59 to 3.31) 27 (9)
Pseudonormal filling pattern (grade 2) 37 (38.5) 37 (35.9) 1.11 (0.78 to 1.57) 123 (40)
Restrictive pattern (grade 3) 1 (1.0) 1 (1.0) 1.18 (0.08 to 18.43) 3 (1)
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Primary outcome (2016 definition),11 n/N (%)
Diastolic and/or systolic dysfunction
postpartum
8/100 (8.2) 11/107 (10.3) 0.78 (0.33 to 1.86) 31 (10)
Systolic dysfunction (yes/no) defined
as left ventricular ejection fraction
< 55%
8/98 (8.2) 11/102 (10.8) 0.76 (0.32 to 1.80) 31 (10)
Diastolic dysfunction (yes/no)
(> 50%/≥ 3–4 positive)
1/100 (1.0) 0/107 (0.0) NA 5 (2)
Average E/e′ > 14 1/96 (1.0) 2/99 (2.0) 0.52 (0.05 to 5.59) 1 (1.0)
Septal e′ velocity < 7 cm/second
or lateral e′ velocity < 10 cm/second
15/96 (15.6) 13/103 (12.6) 1.24 (0.62 to 2.46) 45 (14.0)
Tricuspid regurgitant velocity
> 2.8 m/second
1/100 (1.0) 0/107 (0) – 3 (0.9)
Left atrial volume index (> 34ml/m2) 4/98 (4.1) 3/106 (2.8) 1.44 (0.33 to 6.28) 13 (4.0)
Diastolic dysfunction criteria present, n (%) N = 100 N = 107
0 82 (82.0) 90 (84.1) 257 (80.0)
1+ 16 (16.0) 16 (15.0) – 58 (18.0)
2+ 1 (1.0) 1 (0.9) – 5 (2.0)
≥ 3+ 1 (1.0) 0 (0.0) – 1 (0)
Secondary outcomes
Haemodynamic, mmHg [mean (SD)] N = 100 N = 107
Systolic blood pressure 124 (14) 123 (17) 1.48 (–2.88 to 5.85) 123 (16)
Diastolic blood pressure 76 (13) 75 (13) –0.59 (–2.96 to 4.14) 76 (13)
Hypertension prevalence (on
antihypertensive treatment with or
without systolic BP > 140mmHg with
or without diastolic BP > 90mmHg
72 (72) 76 (71) 1.01 (0.85 to 1.20) 229 (71)
Biomarkers at 6-month follow-up, n (%) N = 92 N = 100
Highly sensitive cTnI > 16 ng/l 1 (1) 1 (1) 1.09 (0.07 to 17.13) 4 (1.4)
N-terminal pro-brain natriuretic
peptide > 100 ng/l
10 (11) 15 (15) 0.72 (0.34 to 1.52) 38 (13.2)
cMyC > 87 ng/l 1 (1) 1 (1) 1.10 (0.07 to 17.31) 2 (0.7)
Echocardiography parameters, mean (SD)
Relative wall thickness (ratio) 0.35 (0.06) 0.35 (0.07) 0.00 (–0.02 to 0.01) 0.35 (0.06)
Left ventricular mass index (g/m2) 63.3 (16.4) 66.7 (14.7) –3.41 (–7.69 to 0.87) 65.1 (14.8)
LV mass (g) 122 (31) 128 (36) –5.73 (–14.89 to 3.42) 125 (32)
Stroke volume (ml) 64.1 (10.5) 62.4 (11.6) 1.69 (–1.37 to 4.74) 62.6 (11.4)
Cardiac output (l/minute) 4.8 (0.9) 4.7 (1.0) 0.12 (–0.14 to 0.39)
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Geometric and haemodynamic parameters
Left ventricular geometry, n (%) N = 100 N = 107
Normal 84 (84) 88 (82) Referent group 265 (83)
Concentric remodelling 14 (14) 18 (17) 0.84 (0.44 to 1.60) 53 (17)
Eccentric remodelling 2 (2) 1 (1) 2.07 (0.19 to 22.41) 3 (1)
LV global cardiac parameters, mean (SD) N = 100 N = 107
Left ventricular ejection fraction 57.9 (4.7) 58.4 (3.9) –0.49 (–1.70 to 0.70) 58.5 (4.4)
E/A ratio 1.37 (0.41) 1.40 (0.43) –0.02 (–0.14 to 0.09) 1.37 (0.39)
Average E/e′ 6.95 (2.07) 7.24 (2.21) –0.28 (–0.89 to 0.32) 7.07 (1.98)
Lateral e′ velocity (cm/second) 0.14 (0.04) 0.14 (0.03) 0.00 (–0.01 to 0.01) 0.14 (0.03)
Septal e′ velocity (cm/second) 0.10 (0.02) 0.10 (0.02) 0.00 (–0.01 to 0.01) 0.10 (0.02)
Tricuspid regurgitant velocity
(m/second)
1.46 (0.79) 1.47 (0.83) –0.01 (–0.23 to 0.21) 1.49 (0.79)
Left atrial volume index (ml/m2) 20.3 (6.6) 21.7 (6.5) –1.42 (–3.22 to 0.39) 21.1 (6.7)
Myocardial mechanics
LV longitudinal parameters, mean (SD)
Peak global LV longitudinal strain (%) –16.9 (3.4) –16.9 (3.2) –0.02 (–0.95 to 0.90) –17.0 (3.3)
Peak global LV longitudinal strain
rate (%·s–1)
–0.89 (0.2) –0.9 (0.2) 0.03 (–0.03 to 0.08) –0.89 (0.20)
LV basal parameters, mean (SD)
Basal radial strain (%) 24.5 (15.1) 26.4 (18.3) –1.95 (–6.59 to 2.70) 24.7 (16.0)
Basal radial strain rate (%·s–1) 1.42 (1.13) 1.43 (0.92) 0.00 (–0.29 to 0.28) 1.40 (0.95)
Basal circumferential strain (%) –17.84 (5.82) –17.32 (5.75) –0.51 (–2.12 to 1.09)–17.57 (5.98)
Basal circumferential strain rate (%·s–1) –1.12 (0.37) –1.09 (0.37) –0.03 (–0.13 to 0.07) –1.10 (0.38)
LV apical parameters, mean (SD)
Apical radial strain (%) 25.1 (13.3) 24.9 (15.7) –0.20 (–4.51 to 4.12) 24.8 (17.7)
Apical radial strain rate (%·s–1) 1.3 (1.1) 1.2 (0.6) –0.14 (–0.40 to 0.12) 1.3 (0.9)
Apical circumferential strain (%) –22.0 (7.3) –21.6 (7.1) 0.34 (–1.78 to 2.47) –21.6 (7.1)
Apical circumferential strain rate
(%·s–1)
–1.3 (0.5) –1.3 (0.4) 0.00 (–0.14 to 0.14) –1.3 (0.5)
BP, blood pressure; cMyC, cardiac myosin binding protein C; LV, left ventricular; NA, not applicable.
a Graded 1–3 using the median value from the classification of the variables E/A (early to late diastole peak
transmitral velocity ratio), deceleration time of E wave (DT) and isovolumetric relaxation time (IVRT) into the
following groups:
l E/A: < 0.73; 0.73–2.33; > 2.33
l DT: > 194ms; 138–194ms; < 138 ms
l IVRT; > 83ms; 51–83ms; < 51ms
b Effect measure adjusted for gestational age at study entry.
E/e′ refers to the ratio of the peak early mitral inflow velocity (E) over the early diastolic mitral annular velocity (e′).
As not every echocardiography parameter was available on each examination, individual denominators are shown
where applicable.
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women had a left ventricular ejection fraction < 55% 6 months postpartum. Similarly, using the more
recent 2016 classification for systolic and diastolic dysfunction, no differences were observed in
systolic (RR 0.76, 95% CI 0.32 to 1.80) or any of the diastolic dysfunction parameters. Hypertension
prevalence, defined as on antihypertensive treatment with or without systolic blood pressure
> 140 mmHg and with or without diastolic blood pressure > 90 mmHg at 6 months postpartum, was
similar between those managed with planned delivery and those expectantly managed (RR 1.01, 95% CI
0.85 to 1.20) but, overall, was present in 71% of the cohort. No significant differences were observed
in any of the cardiac parameters including geometric and haemodynamic parameters, left ventricular
global cardiac parameters, myocardial mechanics and left ventricular basal or apical parameters
between those women with planned delivery and those who were expectantly managed (see Table 3).
The high prevalence of systolic and/or diastolic dysfunction or persistent hypertension was not
explained by pre-existing chronic hypertension because when these women were excluded (n = 37,
11%), systolic and/or diastolic dysfunction was evident in 49.5% of women and hypertension was
evident in 68.7% of women.
Mean time from enrolment to delivery was 2.5 [standard deviation (SD) 1.9] days in the planned
delivery group compared with 6.8 (SD 5.3) days in the expectant management group. No differences
were observed between groups in cardiorespiratory outcomes prior to discharge from hospital nor in
any systolic or diastolic blood pressure measurements (Table 4).











Cardiorespiratory outcomes prior to discharge from hospital
Positive inotropic support, n (%) 0 (0.0) 0 (0.0) – 0 (0.0)
Infusion of a third parenteral
antihypertensive drug, n (%)
0 (0.0) 0 (0.0) – 1 (0.3)
Myocardial ischaemia or
infarction, n (%)
1 (1.0) 0 (0.0) – 1 (0.3)
SpO2 < 90%, n (%) 1 (1.0) 0 (0.0) – 1 (0.3)
≥ 50% FiO2 for > 1 hour, n (%) 0 (0.0) 0 (0.0) – 0 (0.0)
Intubation (other than for caesarean
section), n (%)
0 (0.0) 0 (0.0) – 0 (0.0)
Pulmonary oedema, n (%) 0 (0.0) 0 (0.0) – 0 (0.0)
Time from enrolment to delivery (days)
mean (SD)
2.5 (1.9) 6.8 (5.3) MD –3.83
(–5.61 to –2.06)
5.7 (5.0)
Gestational age at delivery
(weeks), mean (SD)
35.9 (0.8) 36.4 (1.0) MD –0.55
(–0.80 to –0.29)
36.4 (1.0)
Highest systolic BP enrolment to delivery
(mmHg), mean (SD)
156 (17) 164 (15) MD –8.06
(–12.47 to –3.65)
162 (16)
Highest diastolic BP enrolment to
delivery (mmHg), mean (SD)
94 (10) 97 (13) MD –3.16
(–6.27 to –0.04)
96 (11)
Highest systolic BP delivery to hospital
discharge (mmHg), mean (SD)
154 (15) 157 (17) MD –3.58
(–7.99 to 0.83)
156 (16)
Highest diastolic BP delivery to
hospital discharge (mmHg), mean (SD)
90 (13) 93 (14) MD –3.09
(–6.84 to 0.66)
92 (13)
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The only variables affecting development of systolic and/or diastolic dysfunction at 6 months postpartum
(2009 definition)10 were maternal BMI [adjusted odds ratio (OR) 1.33 per 5 kg/m2, 95% CI 1.12 to 1.59
per 5 kg/m2] and maternal age (adjusted OR 2.16, 95% CI 1.44 to 3.22 per 10 years) (Table 5). Interval
from study enrolment to delivery was not associated with development of the primary outcome. There
were no significant predictor variables for systolic and/or diastolic dysfunction at 6 months postpartum by
the updated 2016 definition11 (Table 6). Inclusion of antenatal values of highly sensitive cardiac troponin-I
did not alter the results. All women in the planned delivery group received the trial intervention, although
this was not always initiated within 48 hours as intended. Of the women allocated to the planned delivery
group, 105 out of 133 (79%) had delivery initiated within 48 hours (see Figure 1).











Birth centile < 10th centile, n (%) 27 (24.5) 35 (29.7) RR 0.83
(0.54 to 1.27)
105 (30.3)
Birth centile < 3rd centile, n (%) 7 (6.4) 9 (7.6) RR 0.83
(0.32 to 2.16)
31 (9)
BP, blood pressure; IQR, interquartile range; MD, mean difference; MedD, median difference.
a Calculated using INTERGROWTH centiles.37
TABLE 5 Effect of baseline characteristics on the development of cardiovascular dysfunction (2009 definition)10 at
6 months postpartum (all women)
Unadjusted OR (95% CI) Adjusted OR (95% CI)a
At enrolment variables
Systolic BP (per 10 mmHg) 1.000 (0.999 to 1.002) 1.000 (0.998 to 1.002)
Diastolic BP (per 10 mmHg) 1.001 (0.998 to 1.003) 1.001 (0.999 to 1.003)
Height (per 10 cm) 1.042 (0.768 to 1.414) 1.010 (0.736 to 1.386)
Weight (per 1 kg) 1.016 (1.004 to 1.027) 1.000 (0.969 to 1.031)
BMI (per 5 kg/m2) 1.294 (1.091 to 1.534) 1.334 (1.118 to 1.592)
Age (per 10 years) 2.034 (1.375 to 3.008) 2.156 (1.444 to 3.217)
Smoking status: current 1.797 (0.648 to 4.983) 1.773 (0.624 to 5.037)
cTnI at enrolment (> 16 ng/l) 0.993 (0.313 to 3.150) 1.044 (0.322 to 3.380)
Post-enrolment variables
Time from study recruitment to delivery 0.873 (0.636 to 1.197) 0.986 (0.709 to 1.373)
Highest systolic BP enrolment to delivery (per 10 mmHg) 1.000 (0.999 to 1.002) 1.000 (0.999 to 1.002)
Highest diastolic BP enrolment to delivery (per 10 mmHg) 1.001 (0.999 to 1.003) 1.001 (0.999 to 1.003)
Adverse maternal event (dichotomous)b 1.148 (0.701 to 1.881) 1.155 (0.688 to 1.940)
Gestational age at delivery 0.993 (0.963 to 1.024) 0.990 (0.958 to 1.023)
BP, blood pressure.
a Adjusted for BMI and age.
b Adverse maternal event is defined using the PHOENIX study protocol as a composite of maternal morbidity adapted
from the fullPIERS model for prediction of pre-eclampsia adverse events,16 which will include central nervous system,
cardiorespiratory, haematological, hepatic and renal outcomes, together with placental abruption, intensive care unit
admission and confirmed severe systolic hypertension (≥ 160mmHg). In the PHOEBE study, the clinical event will not
include confirmed severe systolic hypertension.
Note
Adjusted odds ratios in bold indicate significant odds ratios.
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Overall, 8% (n = 25) of women had their clinical echocardiograms escalated by the trial cardiologist
with clinical follow-up recommended. These were for a combination of structural (n = 8), valvular
(n = 8), functional (n = 9) or combined (n = 2) findings. These clinical escalations accounted for 12% of
those with the primary outcome, with 88% of those with systolic and/or diastolic dysfunction not
requiring clinical escalation.
TABLE 6 Effect of baseline characteristics on the development of systolic and/or diastolic dysfunction (2016 definition)11
at 6 months postpartum (n= 321)
Unadjusted OR (95% CI)
At enrolment variables
Systolic BP (per 10 mmHg) 0.999 (0.996 to 1.001)
Diastolic BP (per 10 mmHg) 0.999 (0.996 to 1.003)
Height (per 10 cm) 1.157 (0.688 to 1.949)
Weight (per 1 kg) 1.005 (0.988 to 1.023)
BMI (per 5 kg/m2) 1.058 (0.815 to 1.373)
Age (per 10 years) 1.161 (0.621 to 2.172)
Smoking status: current 1.310 (0.284 to 6.054)
Post-enrolment variables
Time from study recruitment to delivery 0.958 (0.567 to 1.617)
Highest systolic BP enrolment to delivery (per 10 mmHg) 0.999 (0.997 to 1.001)
Highest diastolic BP enrolment to delivery (per 10 mmHg) 1.002 (0.998 to 1.005)
Adverse maternal event (dichotomous)a 0.677 (0.310 to 1.480)
Gestational age at delivery 1.018 (0.705 to 1.471)
BP, blood pressure.
a Adverse maternal event is defined using the PHOENIX study protocol as a composite of maternal morbidity adapted
from the fullPIERS model for prediction of pre-eclampsia adverse events,16 which will include central nervous
system, cardiorespiratory, haematological, hepatic and renal outcomes together with placental abruption, intensive
care unit admission as well as confirmed severe systolic hypertension (≥ 160mmHg). In the PHOEBE study, the
clinical event will not include confirmed severe systolic hypertension.
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In this randomised controlled trial of women with late preterm pre-eclampsia, planned delivery didnot reduce cardiovascular dysfunction at 6 months postpartum. The adverse cardiovascular sequelae
of preterm pre-eclampsia are substantial; 10% of women with preterm pre-eclampsia had a left
ventricular ejection fraction < 55%, 71% remained hypertensive and 49% of women had evidence of
impaired diastolic dysfunction of undetermined long-term clinical importance 6 months postpartum.
Women in the planned delivery group had a median shortening of pregnancy from enrolment to
delivery of 4 days, but this did not result in decreased hypertension or cardiovascular dysfunction
compared with those managed with usual care by expectant management. Only elevated BMI and
higher age at enrolment predicted the occurrence of postpartum systolic and/or diastolic dysfunction.
Previous systematic reviews and meta-analyses describe an association between pregnancies
complicated by pre-eclampsia and long-term adverse cardiovascular morbidity and mortality including
hypertension, myocardial infarction (13-fold increase), major cardiovascular events (13-fold increase),
heart failure (eightfold increase), stroke (14-fold increase) and death (sixfold increase). We are unaware
of any published randomised controlled trials evaluating the impact of timing of delivery on subsequent
maternal cardiovascular function. This large, multicentre trial represents contemporaneous management
of women with late preterm pre-eclampsia followed up by detailed standardised blood pressure and
echocardiography assessment at 6 months postpartum. Our cohort sample size (321 women) is, to our
knowledge, considerably larger than that of any other postpartum cardiovascular study previously
performed, and the involvement of 28 centres throughout the UK makes this representative of the UK
pregnant population. The randomised design allowed us a unique opportunity to explore the impact of
timing of delivery on postpartum cardiovascular function.
The strengths of this study include a sufficiently large sample of women with late preterm pre-eclampsia
from 28 centres throughout the UK completing a detailed 6-month postpartum cardiovascular assessment
to describe the burden of cardiovascular disease in this population, linking pre-eclampsia with longer-term
cardiovascular disease. The trial was conducted to rigorous standards, with a prespecified protocol
without changes. The findings are likely to be generalisable to similar health-care settings because it was
undertaken in a large number of maternity units across England and Wales, with a diverse representation
of women in terms of both demography and disease spectrum. More than half of the eligible women who
were approached agreed to participate in the trial, which indicated agreement of equipoise in this scenario.
Echocardiography was performed by multiple echocardiographers throughout England and Wales,
representative of cardiology units throughout the NHS. We have reported all prespecified secondary
outcomes, interpreting them cautiously.
The limitations of the trial include a change in the international definition of systolic and/or diastolic
dysfunction, such that interpretation of the findings needs to be undertaken in the light of the
prespecified 2009 definition10 and the later 2016 definition.11 Our results reflect systolic and diastolic
definitions used first in 2009 and which were then updated in 2016. We acknowledge that there is an
interim group with a left ventricular ejection fraction between 50% and 55% and further prospective
follow-up would help our understanding of the implications of this impairment in women following
pregnancy. We, a priori, utilised the independent definition of systolic and/or diastolic dysfunction for
this particular patient group as defined by Melchiorre et al.,24 adapted from recommendations of the
European Association of Echocardiography and American Society of Echocardiography10 with adjustments
for age, the higher circulating volume in pregnancy and the acute nature of pre-eclampsia in an otherwise
previously normal cardiovascular system.24 Newer non-pregnant specific definitions (ASE/EACVI guidelines
2016)11 result in lower prevalence of diastolic dysfunction if applied, but cardiovascular morbidity is still
evident and prevalent. There was a relatively short difference of a median 4 days in those managed with
planned delivery than in those managed expectantly, and it is likely that this difference may not have been
sufficiently long to result in detectable differences in cardiovascular function at 6 months postpartum.
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Approximately one-third of the women recruited for this study had declined participation in the
PHOENIX study and as a result were included as a non-randomised expectant management (usual-care)
group. Results across all groups were very similar. We did not recruit women with a healthy pregnancy,
as our primary research question was whether or not shortening of pregnancy after diagnosis of
preterm pre-eclampsia altered the prevalence of cardiovascular dysfunction at 6 months postpartum.
We considered sources of possible bias for our trial. Selection bias into the trial was unlikely because
of the randomisation process, which included robust allocation sequence concealment such that
determining the next allocation was not possible. Performance and detection bias were possible
because it was not possible to mask the participating clinicians, the participating women or the data
collectors because the timing of delivery was contained within maternity records where morbidity
was recorded. However, the trial echocardiographer was masked to randomisation groups and each
echocardiogram was therefore read independent of the knowledge of trial allocation.
There was expected attrition to the 6-month follow-up of around 20% in both groups, but data
completeness of pregnancy outcomes was high (> 99%). The study was originally powered for an
analysis of 322 women (161 women in two treatment groups). However, it became apparent that a
group of eligible women chose not to consent to the main randomised comparison in the PHOENIX
study but would consent for the observational PHOEBE study, with all women in this group following
usual care, which was expectant management. The aims of the PHOEBE study were primarily to
explore the mechanism behind the effect of the intervention (timing of delivery) and to provide an
understanding of postpartum cardiovascular dysfunction after preterm pre-eclampsia. We acknowledge
that this study was underpowered for examining the effect of the intervention. The primary outcome
event rate was also lower than expected by both 200910 and 2016 guidelines.11 For the evaluation
of the effect of the intervention, the two randomised groups were compared. As there was no signal
of a significant effect in the secondary outcomes that would suggest that we had missed an important
difference in the primary outcome (likely to be related to the much shorter separation in time between
randomisation and initiation of delivery between the two groups than anticipated), we also combined
all women recruited to provide an overall cohort of 321 women in which to complete the prognostic
assessment (see Table 5) and to present a detailed cardiovascular assessment on a large prospective
cohort of women with preterm pre-eclampsia.
A recent systematic review summarised 36 studies of maternal cardiovascular function involving
815 women at time of disease with pre-eclampsia. This study demonstrated that increased vascular
resistance and left ventricular mass were the most consistent findings in pre-eclampsia.38 Differentiating
features of a pregnancy complicated by pre-eclampsia from normal pregnancy include left ventricular
wall thickness of ≥ 1.0 cm, exaggerated reduction in early diastole/atrial contraction and lateral e′
of < 14 cm/second, which are the markers of diastolic dysfunction. Reduced stroke volume, diastolic
dysfunction and left ventricular remodelling are most marked in severe and early-onset pre-eclampsia.24,35,39
Our finding of cardiovascular dysfunction and persistent hypertension in the majority of women following
preterm pre-eclampsia is in keeping with other single-centre observational studies.40–49 However, none was
multicentre nor designed to examine different maternal delivery strategies. Our finding of 71% of women
with preterm pre-eclampsia remaining hypertensive 6 months postpartum is higher than reported in
larger population-based cohorts, highlighting high levels of presumed undiagnosed hypertension.50
As the PHOENIX study has now reported, it is unlikely that the opportunity will arise for other investigators
to examine whether or not timing of delivery has an impact on cardiovascular function using such a
randomised approach. Developing accurate validated prognostic tools to best identify those at highest
risk of cardiovascular dysfunction remains challenging, and postpartum intervention strategies must
now be explored to reduce this cardiovascular burden of disease.
We have demonstrated that the burden of postpartum cardiovascular dysfunction following preterm
pre-eclampsia in these women, not otherwise identified as having morbidity, is high. In low-resource
health-care settings and developing countries where underdetected comorbidities including chronic
DISCUSSION
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hypertension are high and cases of fulminant eclampsia prevalent (incidence 1.4%),51 the burden of
cardiovascular morbidity is likely much higher. Recent US data suggest stagnation in the improvements
in incidence and mortality of cardiovascular disease, specifically among younger women.52 It is
imperative that we understand the mechanisms that contribute to worsening risk factor profiles in
young women to reduce future cardiovascular morbidity and mortality. This is acknowledged in the
2030 Agenda for Sustainable Development,53 which aims to reduce by one-third premature mortality
from non-communicable diseases, with cardiovascular disease being the leading cause of death from
such diseases.
Two decades of research have documented an association between pre-eclampsia and major
cardiovascular disorders in later life.2,3,54,55 Despite this body of evidence, usual practice after a pregnancy
complicated by preterm pre-eclampsia is no specific follow-up. It is recognised by the Joint British
Societies, which includes the British Cardiac Society, Heart UK and the British Hypertension Society,
that pregnancy and infancy are good opportunities for education and intervention.56 Furthermore, they
endorse intensive risk factor lowering in individuals with high risk factors that cause cardiovascular
disease. Women with preterm pre-eclampsia are at increased risk of cardiovascular disease later in
life compared with those without preterm pre-eclampsia. In addition, compared with women without
hypertension in pregnancy, women who have had one or more pregnancies affected by pre-eclampsia
have been shown to have an increased hazard ratio of 1.9 (95% CI 1.53 to 2.35) for any stroke, 1.67
(95% CI 1.54 to 1.81) for cardiac atherosclerotic events, 1.82 (95% CI 1.34 to 2.46) for peripheral events,
2.13 (95% CI 1.64 to 2.76) for heart failure, 1.73 (95% CI 1.38 to 2.16) for atrial fibrillation, 2.12 (95% CI
1.49 to 2.99) for cardiovascular deaths and 4.47 (95% CI 4.32 to 4.62) for chronic hypertension.2 This
study has provided mechanistic information on how subsequent clinical cardiovascular events may
be mediated through impaired cardiac function identifiable at 6 months after preterm pre-eclampsia
and highlights the postpartum period as an opportunity for early intervention prior to sustained and
irreversible damage. There is increasing interest in the role of lifestyle and therapeutic interventions
(e.g. with angiotensin-converting enzyme inhibitors) to reduce subsequent cardiovascular risk. This study
provides a body of evidence for postpartum cardiac functional impairment and demonstrates the need
for further research into early intervention, particularly relating to novel therapeutic pathways.
In conclusion, our study confirms that late preterm pre-eclampsia is associated with substantial
postpartum cardiovascular dysfunction. The relatively short delay in those expectantly managed
(compared with planned delivery) does not worsen this cardiovascular dysfunction. Ten per cent of
women with preterm pre-eclampsia had a left ventricular ejection fraction < 55%, 71% remained
hypertensive and 49% of women had evidence of impaired diastolic dysfunction of undetermined
long-term clinical importance 6 months postpartum. Further follow-up would be useful to understand
the longer-term cardiovascular implications of these findings and whether these parameters relate to
hypertension, age or increased BMI. Pre-eclampsia should not be considered a self-limiting disease
of pregnancy alone. This research improves our understanding of the mechanistic processes linking
pre-eclampsia with maternal cardiovascular impairment. The evidence suggests that expectant
management of preterm pre-eclampsia does not worsen postpartum cardiovascular dysfunction, and
women can be reassured that prolongation of a pregnancy affected by preterm pre-eclampsia will not
further worsen their cardiovascular health. The study informs counselling of women with pre-eclampsia
around future risks and also identifies the postpartum period as a critical area to target in future
intervention studies.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to
make better use of information from people’s patient records, to understand more about disease,
develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe
and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make
sure that it is stored and used responsibly. Everyone should be able to find out about how patient
data are used. #datasaveslives You can find out more about the background to this citation here:
https://understandingpatientdata.org.uk/data-citation.
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